Published in Vaccine Weekly, December 21st, 2005
According to recent research from Switzerland and Germany, "Vaccine strategies that target dendritic cells (DC) in order to elicit immunity against tumors are the subject of intense research."
"For the induction and maintenance of antitumor immunity, CD4+ helper T cells are often required, which need to see appropriate MHC class II-peptide complexes on DC. So far, it remained widely unclear what type of tumor cells can feed the MHC class II processing pathway of DC with what type of antigens."
"[In our article]...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly